



Dedicated to Rare Diseases

FOR IMMEDIATE RELEASE

SYNAGEVA BIOPHARMA RECEIVES ORPHAN DRUG DESIGNATION FOR SBC-102 FOR LYSOSOMAL ACID LIPASE DEFICIENCY

WALTHAM, Mass, July 7, 2010 -- [Synageva BioPharma Corp.](#), a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease (CESD), a condition for which there is currently no approved treatment.

As a result of the orphan drug designation, Synageva BioPharma will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, waiver of the FDA filing and registration fees, and seven years of market exclusivity upon approval. U.S. orphan drug designation is granted to a product that treats a rare disease, a condition that affects fewer than 200,000 Americans.

About Synageva BioPharma Corp.

Synageva BioPharma Corp. is dedicated to discovering, developing and commercializing therapies for patients with rare conditions and high unmet medical need. The Company has developed a pipeline of novel therapeutics for underserved populations and has assembled a team with a proven record of bringing orphan therapies to patients. Synageva BioPharma has the ability to use its proprietary protein expression technology (SEP™), which due to its flexibility, scalability and consistency of end product is uniquely suited for the development and commercialization of personalized medicines for patients with rare diseases. Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.

###

Company Contact:

Chris Heberlig
Synageva BioPharma Corp.
Tel: (781) 890-1111
chris.heberlig@synageva.com

Media Contact:

Michele Parisi
BioComm Network
Tel: (925) 429-1850
mparisi@biocommnetwork.com